JP2024522373A5 - - Google Patents

Info

Publication number
JP2024522373A5
JP2024522373A5 JP2023576009A JP2023576009A JP2024522373A5 JP 2024522373 A5 JP2024522373 A5 JP 2024522373A5 JP 2023576009 A JP2023576009 A JP 2023576009A JP 2023576009 A JP2023576009 A JP 2023576009A JP 2024522373 A5 JP2024522373 A5 JP 2024522373A5
Authority
JP
Japan
Prior art keywords
cancer
pharmaceutically acceptable
independently selected
acceptable salt
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023576009A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024522373A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2022/055384 external-priority patent/WO2022259204A1/en
Publication of JP2024522373A publication Critical patent/JP2024522373A/ja
Publication of JP2024522373A5 publication Critical patent/JP2024522373A5/ja
Pending legal-status Critical Current

Links

JP2023576009A 2021-06-11 2022-06-09 Dnaポリメラーゼシータ阻害剤としてのo結合チアジアゾリル化合物 Pending JP2024522373A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163209555P 2021-06-11 2021-06-11
US63/209,555 2021-06-11
US202263319826P 2022-03-15 2022-03-15
US63/319,826 2022-03-15
PCT/IB2022/055384 WO2022259204A1 (en) 2021-06-11 2022-06-09 O-linked thiadiazolyl compounds as dna polymerase theta inhibitors

Publications (2)

Publication Number Publication Date
JP2024522373A JP2024522373A (ja) 2024-06-18
JP2024522373A5 true JP2024522373A5 (https=) 2025-06-13

Family

ID=82358548

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023576009A Pending JP2024522373A (ja) 2021-06-11 2022-06-09 Dnaポリメラーゼシータ阻害剤としてのo結合チアジアゾリル化合物

Country Status (13)

Country Link
US (1) US20240287080A1 (https=)
EP (1) EP4352055A1 (https=)
JP (1) JP2024522373A (https=)
KR (1) KR20240044412A (https=)
AU (1) AU2022289762B2 (https=)
BR (1) BR112023025245A2 (https=)
CA (1) CA3222078A1 (https=)
CL (1) CL2023003671A1 (https=)
CO (1) CO2023017082A2 (https=)
IL (1) IL308912A (https=)
MX (1) MX2023014665A (https=)
TW (1) TW202315618A (https=)
WO (1) WO2022259204A1 (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023202623A1 (zh) * 2022-04-20 2023-10-26 南京再明医药有限公司 Polq抑制剂化合物及其应用
AU2023352129A1 (en) * 2022-09-29 2025-05-01 Repare Therapeutics Inc. N-(5-substituted-[(1,3,4-thiadiazolyl) or (1,3-thiazolyl)](substituted)carboxamide compounds, pharmaceutical compositions, and methods of preparing the amide compounds and of their use
CN117946138A (zh) * 2022-10-28 2024-04-30 杭州圣域生物医药科技有限公司 并环含氮化合物、其中间体、制备方法和应用
WO2024099336A1 (en) * 2022-11-10 2024-05-16 Danatlas Pharmaceuticals Co., Ltd. Thiadiazolyl derivatives, compositions and uses thereof
JP2025541823A (ja) * 2022-12-09 2025-12-23 グラクソスミスクライン、インテレクチュアル、プロパティー、(ナンバー4)、リミテッド Dnaポリメラーゼシータ阻害剤としてのチアジアゾリル誘導体およびその使用
WO2024149349A1 (zh) * 2023-01-14 2024-07-18 西藏海思科制药有限公司 靶向Polθ的化合物及其用途
TW202502745A (zh) * 2023-02-28 2025-01-16 美商賽堤爾醫療公司 4,5-稠和雙環吡咯啶及4,5-稠和雙環吡咯啶-酮化合物
US12215102B2 (en) * 2023-02-28 2025-02-04 Reglagene, Inc. Compositions and methods for making and using small molecules for tubulin-targeted therapy in the treatment of cancers and related conditions
KR20250153866A (ko) 2023-03-10 2025-10-27 브레이크포인트 테라퓨틱스 게엠베하 Dna 중합효소 세타 억제제
WO2024211836A2 (en) 2023-04-05 2024-10-10 Moma Therapeutics, Inc. Semi-saturated bicyclic derivatives and related uses
WO2024213082A1 (en) * 2023-04-13 2024-10-17 Danatlas Pharmaceuticals Co., Ltd. Thiadiazolone derivatives, compositions and uses thereof
CN121712768A (zh) * 2023-05-30 2026-03-20 宁波新湾科技发展有限公司 噻唑基或噻二唑基酰胺衍生物及其用途
CN121399118A (zh) * 2023-06-02 2026-01-23 成都微芯药业有限公司 Polθ抑制剂及其制备方法和用途
EP4727540A2 (en) * 2023-06-16 2026-04-22 Quantx Biosciences US, Inc. Fused bicyclic heterocyclic or hetero aryl amide compounds
WO2025011617A1 (zh) * 2023-07-12 2025-01-16 杭州圣域生物医药科技有限公司 并环杂芳环类化合物、其中间体、制备方法和应用
WO2025016391A1 (zh) * 2023-07-18 2025-01-23 南京再明医药有限公司 噻唑并吡嗪类化合物及其应用
CN121773109A (zh) * 2023-07-27 2026-03-31 北京丹擎医药科技有限公司 PolQ降解剂及其组合物和应用
WO2025036490A1 (zh) * 2023-08-17 2025-02-20 海思科医药集团股份有限公司 一种DNA聚合酶θ抑制剂及其用途
KR20260040065A (ko) * 2023-09-01 2026-03-23 항저우 신알엑스 테라퓨틱스 바이오메디컬 테크놀로지 컴퍼니 리미티드 바이아릴 고리계 화합물, 이의 중간체, 제조 방법 및 용도
CN117229260B (zh) * 2023-11-13 2024-02-27 中国药科大学 DNA聚合酶θ与聚ADP核糖聚合酶1双靶点抑制剂及其制备方法和医药用途
WO2025110780A1 (en) * 2023-11-24 2025-05-30 Daewoong Pharmaceutical Co., Ltd. Novel heterocyclic compounds and pharmaceutical composition comprising the same as dna polymerase theta inhibitors for the prevention or treatment of cancer
WO2025165092A1 (en) * 2024-01-30 2025-08-07 Daewoong Pharmaceutical Co., Ltd. Novel heterocyclic compounds and pharmaceutical composition comprising the same as dna polymerase theta inhibitors for the prevention or treatment of cancer
CN120829441A (zh) * 2024-04-24 2025-10-24 杭州圣域生物医药科技有限公司 一种并环含氮化合物及其中间体的制备方法
CN120829442A (zh) * 2024-04-24 2025-10-24 杭州圣域生物医药科技有限公司 一种并环含氮化合物及其中间体的制备方法
WO2025223483A1 (zh) * 2024-04-24 2025-10-30 杭州圣域生物医药科技有限公司 并环含氮化合物、其晶型及其制备方法和用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7737149B2 (en) * 2006-12-21 2010-06-15 Astrazeneca Ab N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof
US8299070B2 (en) * 2009-11-25 2012-10-30 Japan Tobacco Inc. Indole compounds and pharmaceutical use thereof
EP3034500A1 (en) * 2014-12-17 2016-06-22 Genkyotex Sa Amido thiazole derivatives as NADPH oxidase inhibitors
USRE50319E1 (en) * 2017-10-16 2025-03-04 Dana-Farber Cancer Institute, Inc. Compounds and methods for treating cancer
AU2020282768B2 (en) * 2019-05-31 2023-09-14 Ideaya Biosciences, Inc. Thiadiazolyl derivatives as DNA Polymerase Theta inhibitors
TW202237595A (zh) * 2020-12-02 2022-10-01 美商愛德亞生物科學公司 作為DNA聚合酶θ抑制劑之經取代噻二唑基衍生物

Similar Documents

Publication Publication Date Title
JP2024522373A5 (https=)
TWI869913B (zh) 吡啶并[4,3-d]嘧啶化合物
JP7337907B2 (ja) トル様受容体7(TLR7)アゴニストとしての1H-ピラゾロ[4,3-d]ピリミジン化合物ならびにその方法および使用
ES2581848T3 (es) Derivados de pirrolo[2,3-d]pirimidina como inhibidores de quinasas relacionadas con tropomiosina
JP2023552764A5 (https=)
JP2024539228A (ja) 含窒素四環式化合物、その調製方法及びその医薬的使用
JP2022535227A5 (https=)
CN105611933B (zh) 抗增生性化合物
JP6430670B2 (ja) アルドース還元酵素阻害剤および同使用方法
ES2651765T3 (es) Imidazopiridazinas sustituidas
JP2021525706A (ja) Sting活性化剤としての三環式複素環式化合物
AU2018350980C1 (en) Condensed imidazole derivatives substituted by tertiary hydroxy groups as pi3k-y gamma inhibitors
TW201936197A (zh) 作為trk激酶抑制劑的大環化合物
CN118221698A (zh) Kras g12d抑制剂
TW201628621A (zh) 泛素活化酶抑制劑及輻射之施用
JP2021513551A (ja) 複素環式化合物、その応用及びそれを含有する医薬組成物
JP2017535561A5 (https=)
TW201425314A (zh) 三環旋轉酶抑制劑
CN104903312A (zh) Rho激酶抑制剂
JP2014509298A (ja) アルファへリックスミメティック及びその関連の方法
JP7698653B2 (ja) トール様受容体7(TLR7)アゴニストとしての1H-ピラゾロ[4,3-d]ピリミジン化合物
JP2022547915A (ja) Axlとc-Metキナーゼ阻害活性を有する化合物およびその製造と使用
JP2025502943A (ja) エクトヌクレオチドピロホスファターゼ-ホスホジエステラーゼ1(enpp1)阻害剤およびその使用
CN110156782B (zh) 作为pi3k/mtor抑制剂的吡啶基取代的稠合喹啉化合物
JP2013545775A5 (https=)